Patents by Inventor Kerry W. Fowler

Kerry W. Fowler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140199348
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: February 12, 2013
    Publication date: July 17, 2014
    Applicant: KINETA, INC.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Ernesto J. Muñoz, Myra W. Imanaka, Kerry W. Fowler
  • Patent number: 8779131
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: July 15, 2014
    Assignee: Icos Corporation
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer Treiberg
  • Publication number: 20140121224
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 1, 2014
    Applicant: ICOS CORPORATION
    Inventors: Kerry W. FOWLER, Danwen HUANG, Edward A. KESICKI, Hua Chee OOI, Amy OLIVER, Fuqiang RUAN, Jennifer TREIBERG, Kamal Deep PURI
  • Publication number: 20140121223
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 1, 2014
    Applicant: ICOS CORPORATION
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri
  • Patent number: 8586597
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform PI3K? activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: November 19, 2013
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri
  • Publication number: 20130231356
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: February 12, 2013
    Publication date: September 5, 2013
    Applicant: ICOS CORPORATION
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer TREIBERG
  • Patent number: 8207153
    Abstract: Compounds that inhibit P13K? activity, including compounds that selectively inhibit P13K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: June 26, 2012
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg
  • Publication number: 20120015964
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg
  • Patent number: 7932260
    Abstract: The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3K? activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: April 26, 2011
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg
  • Publication number: 20100256168
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: March 25, 2010
    Publication date: October 7, 2010
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg
  • Publication number: 20100256167
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: March 25, 2010
    Publication date: October 7, 2010
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg
  • Publication number: 20080275067
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: May 12, 2005
    Publication date: November 6, 2008
    Applicant: ICOS CORPORATION
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy R. Oliver, Ruan Fuqiang, Jennifer Treiberg
  • Patent number: 7176229
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: February 13, 2007
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence Edward Burgess, John Joseph Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Patent number: 7087634
    Abstract: Pyrazole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: August 8, 2006
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Carmen C. Hertel, Amy Oliver
  • Patent number: 6998416
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: February 14, 2006
    Assignee: Icos Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Patent number: 6924284
    Abstract: The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula: or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q1, Q2 and Y are those defined herein.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: August 2, 2005
    Assignees: ICOS Corporation, Deltagen Research Labs, LLC
    Inventors: Graham Beaton, Wilna J. Moree, Jaimie K. Rueter, Russell S. Dahl, David L. McElligott, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, Kerry W. Fowler, Danwen Huang, Jaimie E. Bertino, Lisa H. Bourdon, David J. Fairfax, Qin Jiang, Helge A. Reisch, Ren Hua Song, Pavel E. Zhichkin
  • Publication number: 20040152754
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: January 15, 2004
    Publication date: August 5, 2004
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Publication number: 20040087588
    Abstract: The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same.
    Type: Application
    Filed: August 15, 2002
    Publication date: May 6, 2004
    Applicant: ICOS Corporation
    Inventors: Graham Beaton, Wilna J. Moree, Jaimie K. Rueter, Russell S. Dahl, David L. McElligott, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, Kerry W. Fowler, Danwen Huang, Jaimie A. Bertino, Lisa H. Bourdon, David J. Fairfax, Qin Jiang, Helge A. Reisch, Ren Hua Song, Pavel E. Zhichkin
  • Patent number: RE44599
    Abstract: Compounds that inhibit P13K? activity, including compounds that selectively inhibit P13K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: November 12, 2013
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri
  • Patent number: RE44638
    Abstract: The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3K? activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: December 10, 2013
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri